Phase 1 · Raleigh area, NC
Phase 1 clinical trials in Raleigh area, NC
47 recruiting studies have a site in the Raleigh area. This page includes nearby cities such as Durham, Chapel Hill, Cary, Morrisville.
47 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Nalmefene Implant in Healthy Subjects
ReacX Pharmaceuticals, Inc.
- Location
- Morrisville, NC
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study
University of North Carolina, Chapel Hill
- Location
- Chapel Hill, NC + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Raleigh, NC + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Vega Therapeutics, Inc
- Location
- Morrisville, NC + 9 other US sites
- Eligibility basics
- Ages 12–60
- RecruitingPhase 1Overnight stay mentioned
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
GentiBio, Inc
- Location
- Chapel Hill, NC + 8 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
pH1N1 Blinded Challenge Study
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Durham, NC + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
David D'Alessio, M.D.
- Location
- Durham, NC
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 1
Macrophage Regulation of Ozone-Induced Lung Inflammation
Robert Tighe, MD
- Location
- Durham, NC
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersEarly Phase 1
Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking
Duke University
- Location
- Durham, NC
- Eligibility basics
- Ages 18–21
- RecruitingHealthy volunteersPhase 1/Phase 2
Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism
University of North Carolina, Chapel Hill
- Location
- Chapel Hill, NC + 1 other US site
- Eligibility basics
- Ages 18–45
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Durham, NC + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
- Location
- Chapel Hill, NC + 7 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sanofi
- Location
- Wake Forest, NC + 30 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Wake Forest, NC + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Charlotte, NC + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 1/Phase 2
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
AskBio Inc
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Cabaletta Bio
- Location
- Chapel Hill, NC + 17 other US sites
- Eligibility basics
- Ages 12–65
- RecruitingPhase 1
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Disc Medicine, Inc
- Location
- Durham, NC + 10 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc.
- Location
- Durham, NC + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Charlotte, NC + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 1
Study of GS-0415 and How It Works in People With HIV
Gilead Sciences
- Location
- Durham, NC + 14 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X, Inc.
- Location
- Durham, NC + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
- Location
- Chapel Hill, NC + 5 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG
- Location
- Durham, NC + 7 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.